Background: Terminal α2-3 and α2-6 sialylation of glycans precludes further chain elongation, leading to the biosynthesis of cancer relevant epitopes such as sialyl-Lewis X (SLe X ). SLe X overexpression is associated with tumor aggressive phenotype and patients' poor prognosis. Methods: MKN45 gastric carcinoma cells transfected with the sialyltransferase ST3GAL4 were established as a model overexpressing sialylated terminal glycans. We have evaluated at the structural level the glycome and the sialoproteome of this gastric cancer cell line applying liquid chromatography and mass spectrometry. We further validated an identified target expression by proximity ligation assay in gastric tumors. Results: Our results showed that ST3GAL4 overexpression leads to several glycosylation alterations, including reduced O-glycan extension and decreased bisected and increased branched N-glycans. A shift from α2-6 towards α2-3 linked sialylated N-glycans was also observed. Sialoproteomic analysis further identified 47 proteins with significantly increased sialylated N-glycans. These included integrins, insulin receptor, carcinoembryonic antigens and RON receptor tyrosine kinase, which are proteins known to be key players in malignancy. Further analysis of RON confirmed its modification with SLe X and the concomitant activation. SLe X and RON co-expression was validated in gastric tumors.
Introduction
Even more than four decades after declaring "war" on cancer at least 7 million patients die annually from the consequences of this disease, which represents 15% of all deaths worldwide [1, 2] . Gastric cancer is globally the fifth most common cancer with near 1 million cases diagnosed in 2012 [3] and represents the third most common cause of cancer-related death. Due to its usually late diagnosis in already advanced stages it remains difficult to treat even in developed countries. Nowadays, there is no specific serological assay for the screening and diagnosis of gastric cancer, and endoscopy remains the gold standard in the clinical practice. However, the SLe a glycan antigen CA19-9 is currently used for monitoring gastric cancer patients' response to treatment and recurrence [4, 5] . One of the most abundant forms of posttranslational modifications (PTM) of proteins is glycosylation, which is a complex process coordinated by the interplay of numerous glycosyltransferases and glycosidases, resulting in a vast diversity of structures. In cancer the disruption of the glycosylation machinery leads to aberrant expression of short truncated carbohydrate chains, known as cancer-associated simple carbohydrate antigens, and to altered expression of terminal sialylated chains [6, 7] . These cancer-associated antigens are detected in different types of carcinomas and are associated with disease prognosis, constituting a pool of potential cancer biomarkers, especially when combined with information on the carrying proteins.
It has been long recognized that each cancer patient is different regarding prognosis, clinical presentation, tumor response and tolerance to treatment. With the constant improvement in sequencing and other large-scale analytical technologies, molecular tumor profiling has become unprecedentedly feasible [8] . This enables the identification of the unique combination of alterations, especially that of wellestablished cancer-related genes, for each patient and personalize their treatment. This customized attempt of tackling cancer has been on the focus of researchers for a long time, but for many cancer-associated alterations the understanding of the biological consequences and therapy-response implications lags behind [9] .
One typical target of the personalized therapy strategies is the inhibition of activated signaling pathways, either by interfering directly with the receptor activation or interrupting the downstream signaling cascade by blocking specific GTPases [10] . Receptors such as EGFR, c-MET and RON (Recepteur d'Origine Nantais) can be targeted by small molecules or monoclonal antibodies that act as inhibitors by blocking ligand binding and signaling or by antibodies that tag tumor cells for immune response [10, 11] . For instance, the RON receptor tyrosine kinase (also known as macrophage-stimulating protein receptor (MSPR) or MST1R) is constitutively transcribed in many epithelial cells but commonly shows aberrant activation in various tumors due to overexpression and generation of oncogenic variants. Currently several therapeutic agents and monoclonal antibodies targeting RON are tested in clinical and preclinical phases [12] .
Therefore, two main goals in gastric cancer research are the discovery of new biomarkers for early diagnosis [5] and the elucidation of altered mechanisms that can be targeted for the development of novel directed and personalized treatments.
In the present work, we have performed a comprehensive analysis of cellular clones derived from MKN45 gastric carcinoma cells overexpressing the human α2,3-sialyltransferase ST3GAL4. The N-and O-glycomic, sialoproteomic and gene expression analysis were performed using a combination of high-throughput methods which revealed several cancer-associated glycomic alterations and generated a list of 47 putative glycoprotein targets with altered glycosylation in gastric cancer cells. Further characterization of one of the targets, the RON receptor tyrosine kinase, confirmed the altered glycosylation and revealed an increased activation of this oncogene in the gastric cancer cells. Finally, we demonstrate that this altered glycosylation of RON receptor tyrosine kinase occurs in human gastric tumors, showing that glycosylation alterations are an alternative pathway for cancer cells to activate receptors that lead to malignant growth, and which can be targets for personalized therapy in gastric cancer patients.
Material and Methods

Cell culture
The gastric carcinoma cell line MKN45 was obtained from the Japanese Cancer Research Bank (Tsukuba, Japan) and was stably transfected with the full length human ST3GAL4 gene and the corresponding empty vector pcDNA3.1 (Mock) as previously shown [13] . The cells were grown in monolayer culture in uncoated cell culture flasks or cell culture flasks coated with fibronectin or collagen IV (BD BioCoat, BD Biosciences, Franklin Lakes, NJ). Cells were maintained at 37°C in an atmosphere of 5% CO 2 , in RPMI 1640 GlutaMAX, HEPES medium supplemented with 10% fetal bovine serum (FBS), 1% penicillinstreptomycin and in the presence of 0.5 mg/mL G418 (all from Invitrogen, Waltham, MA). Cell culture medium was replaced every two days.
Quantitative real-time PCR (RT-PCR)
Total RNA extracts from mock and ST3GAL4 transfected cell lysates were isolated with TRI Reagent (Sigma-Aldrich, St. Louis, MO) and converted into cDNA using the SuperScript® II Reverse Transcriptase (Invitrogen) according to the manufacturer's protocol. The following primers for ST3GAL4 were used applying the protocol previously described [13] : for5ʹ-cctggtagctttcaaggcaatg-3ʹ; rev5ʹ-cctttcgcacccgcttct-3ʹ. Expression level of 18S rRNA was used for mRNA expression normalization (for5ʹ-cgccgctagaggtgaaattc-3ʹ; rev5ʹ-cattcttggcaaatgctttcg-3ʹ).
RNA next generation sequencing
Total RNA was extracted as previously described in Section 2.2. The mRNAs of over 20,000 primed targets were sequenced by using Ion AmpliSeq Transcriptome Human Gene Expression Kit. The Ion Chef system was used for templating and the loaded chips sequenced using the Ion Proton System (both from Life Technologies). Sequencing data was automatically transfered to the dedicated Ion Torrent server to generate sequencing reads. Reads quality and trimming was performed using Torrent Server v4.2 before read alignment using TMAP 4.2. The TS plugin CoverageAnalysis v4.2 was used to generate reads count. The sequencing was performed in duplicates and sequence reads were normalized to the total read count.
Immunofluorescence (IF)
Cells were grown in 15 μ-Chamber 12 well glass slides (IBIDI, Martinsried, Germany) and either fixed with 4% paraformaldehyde (PFA) or cold acetone for 15 and 5 min, respectively. The IF protocol performed was as previously described [13] using the antibodies and dilutions noted in Table 1 . Samples were examined under a Zeiss Imager.Z1 Axio fluorescence microscope (Zeiss, Welwyn Garden City, UK). Images were acquired using a Zeiss Axio cam MRm and the AxioVision Release 4.8.1 software.
Protein and phosphoprotein arrays
Confluent cells were lysed in lysis buffer 17 or 6 (R&D Systems, McKinley Place, MN) supplemented with 1 mM sodium orthovanadate, 1 mM phenylmethanesulfonylfluoride (PMSF) and protease inhibitor cocktail (Roche, Basel, Switzerland). The protein concentrations of lysates were determined by the DC protein assay (BioRad, Hercules, CA) and the recommended total protein amounts were used for the human non-haematopoietic soluble receptor array, human phospho-RTK array kit and human phospho-kinase array (R&D Systems). The array protocols were performed according to manufacturer's instructions.
Western (WB) and Lectin blotting (LB)
Proteins were obtained from total cell lysates as previously described in Section 2.5. Total lysates were denatured and charged using Laemmli buffer, separated by SDS-PAGE and blotted onto a nitrocellulose membrane (GE Healthcare, Chalfont, UK) in a semi-dry system (BioRad). Membranes were incubated with primary antibodies overnight at 4°C or with biotinylated lectins for 2 h at room temperature (Table 1) . Secondary antibodies or avidin (ABC Standard Kit, Vector Laboratories, Burlingame, CA) conjugated with peroxidase were incubated for 1 h at room temperature. Target proteins were revealed by chemiluminescence using the ECL Western blotting detection reagent and films (both from GE Healthcare).
In situ proximity ligation assay (PLA)
In situ Proximity Ligation Assay (PLA) was performed in acetone fixed cells as described in 2.4 or in paraffin sections from human gastric carcinoma tissues for the detection of co-expression in proximity of SLe X and RON. PLA was performed adapting the procedure previously described [14] . Duolink II reagents (Olink Bioscience, Uppsala, Sweden) were used according to the manufacture instructions. Paraffin sections were dewaxed, rehydrated, antigen retrieval using sodium citrate buffer (10 mM, pH 6. 
Sample preparation for LC-ESI-MS/MS and HILIC-FLD-UPLC analyses
Frozen cell pellets (10 7 cells) were directly resuspended in 7 M urea, 2 M thiourea, 40 mM Tris, 2% CHAPS, 10 mM DTT and 1% protease inhibitor (Sigma-Aldrich, St. Louis, MO). The cell membranes were disrupted by 10 times 10 sec sonication with 16 amplitudes and 1 minute on ice in between, and subsequent shaking at 4°C overnight. To reduce the viscosity of the lysates, the DNA was degraded by adding 1 μl benzonase® nuclease (250 units, Sigma-Aldrich) and 30 min incubation at 37°C. In order to impair refolding of proteins, 25 mM iodoacetamide were added for alkylation during 1 h in the dark. The lysates were centrifuged for 30 min with 14,000 rpm and the supernatants transferred to a fresh tube. Then, solubilized proteins were concentrated by adding 150 μl of supernatant on a 10 kDa cut-off spinfilter (PALL, Port Washington, NY), spinning down for 5 min with 12,000 x g and washing 3 times with 100 μl 50 mM NH 4 HCO 3 , pH 8.4 . N-linked oligosaccharides were released in the spinfilter using 20 μl 50 mM NH 4 HCO 3 and PNGase F (5 mU, Prozyme, Hayward, CA) with incubation at 37°C overnight. Subsequently, the N-glycans were collected by washing 3 times with 20 μl H 2 O and dried in Speedvac. For UPLC analysis samples were further processed as described below and for LC-ESI-MS/MS analysis samples were reduced with 0.5 M NaBH 4 , 10 mM NaOH at 50°C overnight. The O-linked glycans were released from retained glycoproteins in spinfilter using reductive β-elimination (0.5 M NaBH 4 , 50 mM NaOH at 50°C, 16 h). Reactions were quenched with 1 μl of glacial acetic acid and glycan (both N-glycans and O-glycans) samples were desalted and dried as previously described [16] and subjected to LC-ESI-MS/MS analysis.
LC-ESI-MS/MS for N-and O-glycomic analysis
Released glycans were analyzed by LC-ESI-MS/MS using a 10 cm x 250 μm I.D. column, prepared in-house, containing 5 μm porous graphitized carbon (PGC) particles (Thermo Scientific, Waltham, MA). Glycans were eluted using a linear gradient from 0 to 40% acetonitrile in 10 mM NH 4 HCO 3 over 40 min at a flow rate of 10 μl/min. The eluted N-and O-glycans were detected using a LTQ ion trap mass spectrometer (Thermo Scientific) in negative-ion mode with an electrospray voltage of 3.5 kV, capillary voltage of − 33.0 V and capillary temperature of 300°C. Air was used as a sheath gas and mass ranges were defined dependent on the specific structure to be analyzed. The data were processed using the Xcalibur software (version 2.0.7, Thermo Scientific) and manually interpreted from their MS/MS spectra.
Ultra performance liquid chromatography (UPLC)
Released N-glycans were labeled by reductive amination with the fluorophore 2-aminobenzamide (2-AB) (Sigma-Aldrich, St.Louis, MO) with sodium cyanoborohydride in 30% v/v acetic acid in DMSO at 65°C for 2 h. Excess of 2-AB reagent was removed on Glycoworks HILIC cartridges according to the manufacturer's instructions (Waters, Milford, MA) and then concentrated to dryness in speed-vac.
Hydrophilic interaction liquid chromatography (HILIC) of fluorescently labeled N-glycans was carried out on a 1.7 μm BEH glycan column (2.1 mm x 15 mm, Waters, Milford, MA) and analyzed using Waters ACQUITY UPLC® I-class with fluorescence detection. The column temperature was kept at 40°C and the flow rate set to 0.561 mL/min using a linear gradient of 50 mM ammonium formate (pH 4.4) against acetonitrile with ammonium formate increasing from 30% to 47% over a 25 min period. An injection volume of 25 μL sample prepared in 70% v/v acetonitrile was used throughout. Fluorescence detection was achieved using excitation and emission wavelengths of 330 nm and 420 nm, respectively. The 2-AB labeled glycans were digested in 10 μL of 50 mM sodium phosphate, pH 6.0 at 37°C overnight using sialidase S (4 mU, ProZyme) that releases α2-3 linked non-reducing terminal sialic acids (recombinant sialidase from Streptococcus pneumoniae, expressed in Escherichia coli) and sialidase A (5 mU, ProZyme) that releases α2-3/6/8 linked non-reducing terminal sialic acid (recombinant gene from Arthrobacter ureafaciens, expressed in Escherichia coli) to confirm sialic acid linkage. After incubation, enzymes were removed by filtration through a 10 kDa cut-off spinfilter (PALL, Port Washington, NY) and the N-glycans were analysed by HILIC-FLD-UPLC. The system was calibrated by running an external standard of 2AB-dextran ladder (2AB-glucose homopolymer, Ludger, Oxfordshire, UK) alongside the sample runs. A fifth-order polynomial distribution curve was fitted to the dextran ladder and used to allocate GU values from retention times (using Empower 3 software from Waters) [17] .
Cell lysis, protein digestion and iTRAQ labeling
Cell pellets were redissolved in ice-cold Na 2 CO 3 buffer (0.1 M, pH 11) supplemented with protease inhibitor (Roche complete EDTA free), PhosSTOP phosphatase inhibitor cocktail (Roche) and 10 mM sodium pervanadate on ice. The suspensions were tip probe sonicated for 20 s (amplitude = 50%) twice and incubated at 4°C for 1 h. The lysates were then centrifuged at 100,000 × g for 90 min at 4°C to separate soluble proteins from membrane proteins (pellet). The pellets were washed with 50 mM triethylammonium bicarbonate (TEAB) to remove any remaining soluble protein. The supernatants containing soluble proteins were concentrated using 10 kDa cutoff Amicon ultra centrifugal filters units (Millipore, Billerica, MA. USA) while membrane fractions were resuspended directly in 6 M urea and 2 M thiourea.
Soluble and membrane fractions were both reduced in 10 mM DTT for 30 min and then alkylated in 20 mM IAA for 30 min at room temperature in the dark.
Samples were incubated with endoproteinase Lys-C (Wako, Osaka, Japan) for 2 h (1:100 w/w). Following the incubation, the samples were diluted 8 times with 50 mM TEAB (pH 8) and trypsin was added at a ratio of 1:50 (w/w) and left overnight at room temperature. Trypsin digestion was stopped by the addition of 2% formic acid and then the samples were centrifuged at 14,000 × g for 10 min to precipitate any lipids present in the sample. The supernatant was purified using in-house packed staged tips with a mixture of Poros R2 and Oligo R3 reversed phase resins (Applied Biosystem, Foster City, CA, USA). Briefly, a small plug of C18 material (3 M Empore) was inserted in the end of a P200 tip, followed by packing of the stage tip with the resins (resuspended in 100% ACN) by applying gentle air pressure. The acidified samples were loaded onto the micro-column after equilibration of the column with 0.1% trifluoroacetic acid (TFA), washed twice with 0.1% TFA and peptides were eluted with 60% ACN/0.1% TFA. A small amount of purified peptides (1 μl) from each sample was subjected to Qubit assay to determine the concentration, while the remaining samples were dried by vacuum centrifugation. Afterwards, peptides were redissolved in dissolution buffer and a total of 150 μg for each condition was labeled with 4-plex iTRAQ TM (Applied Biosystems, Foster City, CA) as described by the manufacturer. After labeling, the samples were mixed 1:1:1:1 and lyophilized by vacuum centrifugation.
Sialic acid containing glycopeptide enrichment by TiSH protocol
The method used for sialylated glycopeptides enrichment is a modification of the TiSH protocol [18] described in [19] . Briefly, samples were resuspended in loading buffer (1 M glycolic acid, 80% ACN, 5% TFA) and incubated with TiO 2 beads (GL Sciences, Japan, 10 μm; using a total of 0.6 mg TiO 2 beads per 100 μg of peptides). The supernatant containing the unmodified peptides was carefully separated. The TiO 2 beads were sequentially washed with loading buffer, washing buffer 1 (80% ACN, 1% TFA) and washing buffer 2 (20% ACN, 0.1% TFA), saving the washings with the previous supernatant. The bound peptides were eluted with 1.5% ammonium hydroxide by shaking for Results are presented as average ± SD. B. Cells that overexpress ST3GAL4 display an increased expression of the SLe X epitope as shown by immunofluorescence using anti-SLe X antibody (KM93). C. Depiction of the addition of α2-3 sialic acid to Galβ1-4GlcNAc, which is the major reaction that is catalyzed by the sialyltransferase ST3GAL4 as previously described [18] . The glycan structure Galβ1-4GlcNAc is commonly found in both N-and O-glycans and is referred to as type 2 chain. This structure can be further fucosylated leading to an increase of the SLe X glycan epitope. sialylated glycopeptides was dried by vacuum centrifugation and subjected to an enzymatic deglycosylation in 20 mM TEAB buffer using 500 U of PNGase F (New England Biolabs, Ipswich, MA) and 0.1 U of Sialidase A (Prozyme, Hayward, CA) overnight at 37°C. To separate phosphorylated peptides and formerly glycosylated peptides, the samples were subjected to a second TiO 2 enrichment procedure to separate phosphorylated from deglycosylated peptides. The supernatant containing the deglycosylated peptides was saved and the beads were washed with 50% ACN, 0.1% TFA. The washing was added to the supernatant. The deglycosylated fraction was desalted on Oligo R3 staged tip column and dried prior to the HILIC fractionation [19] . All fractions were dried by vacuum centrifugation prior nLC-MS/ MS analysis.
Sialic acid containing glycopeptide analysis by nLC-MS/MS
Samples were resuspended in 6 μL of 0.1% TFA for analysis. Peptides were loaded on an in-house packed Reprosil-Pur C18-AQ (2 cm x 100 μm, 5 μm; Dr. Maisch GmbH, Germany) pre-column and separated on an in-house packed Reprosil-Pur C18-AQ (17 cm x 75 μm, 3 μm; Dr.
Maisch GmbH, Germany) column using an Easy-nLC II system (Thermo Scientific, Bremen, Germany) and eluted at a flow of 250 nL/min. Mobile phase was 95% acetonitrile (B) and water (A) both containing 0.1% formic acid. Depending on the samples, gradient was from 1% to 30% solvent B in 80 The raw data were processed and quantified by Proteome Discoverer (version 1.4.1.14, Thermo Scientific) against SwissProt and Uniprot human reference database by using Mascot (v2.3.02, Matrix Science Ltd, London, UK) and Sequest HT, respectively. Database searches were performed using the following parameters: precursor mass tolerance of 10 ppm, product ion mass tolerance of 0.02 Da, 1 missed cleavages for trypsin, carbamidomethylation of Cys and iTRAQ labelling on protein N-terminal and Lys as fixed modifications, and phosphorylation on S/T/Y and deamidation of Asn as dynamic modifications. The iTRAQ datasets were quantified using the centroid peak intensity with the "reporter ions quantifier" node. Only peptides with up to a q-value of 0.01 (Percolator), Mascot and Sequest HT rank 1, Sequest HT ΔCn of 0.1, cut off value of Mascot score ≥ 18 and a cut-off value of XCorr score for charge states of +1, +2, +3, and +4 higher than 1.5, 2, 2.25 and 2.5, respectively, were considered for further analysis.
Data normalization and significance analysis
Three biological replicates were analysed and submitted to the statistical analysis. The log2 values of the measured intensities were normalized by the median. Modified peptides were merged with the R Rollup function (http://www.omics.pnl.gov) allowing for one-hitwonders and using the mean of the normalized intensities for each peptide. Quantification of proteins was obtained by merging the unmodified peptides with the R Rollup function considering at least 2 unique peptides not allowing for one-hit-wonders and using the mean of the intensities. Then the mean over the experimental conditions for each peptide in each replicate was subtracted in order to merge data from different iTRAQ runs. Formerly sialylated glycopeptides containing the consensus motif for N-linked glycosylation (NXS/T/C; where X # P) were normalized based on the protein expression in each of the replicates. Significant up/down-regulations between experimental conditions were calculated allowing a false discovery rate of 0.05. Therefore, we applied combined limma and rank product tests [20] , subsequently corrected for multiple testing according to Storey.
Since spontaneous deamidation is frequently observed for asparagine residues, especially when the C-terminal amino acid is glycine (NG), the sites with NGS/T/C are considered as only potential glycosylation. However, in order to reduce the contribution from spontaneous deamidation in the final list, we sort first for the N-linked consensus site (NXS/T/C) and then we filter for proteins that are membrane-associated in order to exclude intracellular proteins that are not N-linked glycosylated.
Results
Overexpression of ST3GAL4 leads to increased expression of SLe X
The gastric cancer cell line MKN45 shows low expression levels of the sialyltransferase ST3GAL4 and of the terminal glycan epitope sialyl Lewis X (SLe X ) [13] . We have generated clones of MKN45 cells that were stably transfected with the full length ST3GAL4 resulting in approximately 150 times upregulation of this gene expression (Fig. 1a ). ST3GAL4 has been described to be upregulated in the context of gastric cancer and catalyzes the sialylation of Galβ1-3GalNAc on O-glycans and of type 2 (Galβ1-4GlcNAcβ-) extensions on both N-and O-glycans, an intermediate epitope in the biosynthesis of SLe X [21] [22] [23] . As a consequence of the increased expression of ST3GAL4, the terminal glycan epitope SLe X is overexpressed (Fig. 1) . Previous studies on this cell line have demonstrated increased invasive potential both in vitro and in vivo compared to the mock transfected control cell line [24] .
The N-glycome of ST3GAL4 overexpressing cells is specifically altered in α2-6/3 linked sialic acid content, bisecting and branched structures
To assess the full extent of glycomic alterations in our cell line model we performed a whole N-glycomic analysis based on LC-ESI-MS/MS (Table 1 in [25] ), to gain semi-quantitative and detailed structural information, and HILIC-FLD-UPLC for quantitative comparisons. The HILIC-FLD-UPLC spectra shows no alteration in the major peaks, which are of high-mannose nature and expectedly unaffected by alterations in sialyltransferase levels. This was confirmed by LC-ESI-MS/MS analysis ( Fig. 2a and b) . Moreover, the total amount of sialylated structures was not significantly altered (Fig. 2c) . It should be noted that the structural analysis revealed also several truncated glycans (Table 1 in [25] ) previously described in the MKN45 cell line as free N-glycans [26] . Alterations in free N-glycans are in conformity with their non-truncated equivalents and are thus not further described in this study.
Despite the overall similarity of the N-glycome of cancer cells expressing ST3GAL4 and the control cell line, detailed analysis revealed several specific alterations in the cancer cells expressing ST3GAL4. Our results showed that the sialic acids linked α2-6 were reduced and the α2-3 linked reciprocally increased, indicating a shift of linkage in the ST3GAL4 transfected cells (Fig. 3) . Nevertheless, α2-6 linked sialic acid structures remain a large component of the ST3GAL4 cells' glycome. Since expression levels of sialyltransferases of the ST6 family are unaltered as shown by RNASeq (Supplementary table 1) we hypothesize that the observed isomeric change may be due to competition for the acceptor substrate.
Additionally, bisecting N-glycan structures were significantly decreased (Fig. 4) . The presence of bisecting N-acetylglucosamine excludes the possibility of adding a β1-6 branched arm to the complex N-glycan and therefore often inversely correlates with the amount of large branched structures [27, 28] . In our cancer cell line model, the amount of large and presumably branched complex N-glycans is increased (Fig. 4) .
O-glycomic analysis reveals an increase in truncated O-glycans
Mucin type O-glycosylation is commonly altered in cancer with truncation as the most common aberration [29] . MKN45, as a gastric epithelial derived cancer cell line, produces mainly core 2 O-glycans [30] . Our analyses showed high amounts of sialylated O-glycans in the MKN45 cell line with the majority of structures being decorated with at least one sialic acid (Table 3 in [25] ). However, the overexpression of ST3GAL4 leads to an earlier termination by sialylation and thus, to the formation of truncated O-glycans (Fig. 5) . This is mainly due to the increase in doubly sialylated core 2 structure which accounts for more than 40% of the total O-glycan amount in our transfected cells. On the other hand, O-glycans composed of more than 2 N-acetylhexosamines or hexoses were reduced by approximately 30% (Fig. 5) .
Identification of over 40 glycoproteins with altered glycosylation
The sialoproteomic analysis performed on protein extracts of ST3GAL4 and mock transfected cells revealed glycoproteins that display aberrant glycosylation. The analysis quantified 1566 unique glycopeptides of which 69 had a significantly altered abundance in sialylated Fig. 3 . Sialylation of N-glycans in ST3GAL4 overexpressing cells shows a shift from α2-6 linked towards α2-3 linked. A. Relative quantification of disialylated biantennary structures illustrates the general trend that α2-6 linked sialic acids are reduced whereas α2-3 linked are increased. The quantifications are established by base-peak intensity of extracted ion chromatograms from LC-ESI-MS performed in three biological replicates and presented as average ± SD. Statistical significance was determined by unpaired student's t-test (p-value *b0.05; **b0.01). B. Extracted ionchromatogram for m/z 1184 shows the relative increase of disialylated biantennary structures with α2-3 linked sialic acids when compared to α2-6 linked. Structures were assigned by a combination of MS² spectra (shown below) and α2-3 specific sialidase treatment. C, D. Quantitative HILIC-FLD-UPLC of 2-AB labeled N-glycans confirm that α2-3 carrying species are increased and α2-6 are decreased in ST3GAL4 compared to mock transfected cells. Sialic acid linkage was determined by Sialidase A (releases α2-3,6,8) and Sialidase S (releases α2-3) sialidase treatment experiments. EU: Emission unit. E. Sambucus nigra (SNA, binds α2-6 linked sialic acid) lectin blot reveals that especially proteins in the higher molecular mass area (N75kDa) are significantly less decorated with α2,6-linked sialic acid. N-glycosylation. Of those glycopeptides two showed a decrease in sialylation and the remaining 67 an increase in ST3GAL4 transfected cells, corresponding to an overall total of 47 glycoproteins (Table 5 and 6 in [25] ). Many of the identified glycoproteins have established functions in cellular signaling as either receptors or receptor interacting proteins, in cellular adhesion and migration, or are proteases (Fig. 6) . Among the identified glycoproteins, many well characterized targets that are described to be altered in the context of gastric carcinogenesis were found, such as insulin receptor, CEACAM1, CEA, various integrins and RON [12, [31] [32] [33] .
Activation of altered glycosylated RON receptor tyrosine kinase
Given that the sialoproteomic analysis pointed out a potential alteration of the RON receptor tyrosine kinase glycosylation, we investigated this further, especially since this protein has been shown to be hyperactivated in the context of gastric cancer, contributing in tumorigenesis, malignant progression, angiogenesis, chemoresistance and correlating with bad prognosis [34] [35] [36] [37] [38] . Several mechanisms, including overexpression of this receptor and generation of oncogenic variants, have been described that can account for aberrant activation of RON, however, there are cases in which the cause for this abnormal activation remains unknown [38] [39] [40] . Comparative analysis between ST3GAL4 overexpressing cells and the mock transfected cells revealed that the expression of RON is unaltered at both RNA (Supplementary table  1 ) and protein levels (Fig. 7) , but shows around 4.5 times increased receptor activation in ST3GAL4 overexpressing cells (Fig. 7a, b) , as measured by the increase of phosphorylation of RON. The activated phosphorylated RON protein was observed on the plasma membrane coinciding with the expected localization of fully glycosylated RON (Fig. 7c) .
Altered glycosylation of RON in gastric cancer
In order to confirm the altered glycosylation of RON in the cell line model we used in situ proximity ligation assay (PLA). We demonstrated that RON is aberrantly glycosylated carrying the SLe X epitope in ST3GAL4 transfected cells (Fig. 8) . The localization of RON receptor decorated with SLe X was observed in the cellular membrane. To assess whether the modification of RON occurs also in gastric carcinoma tissues we screened 15 human gastric tumor samples for the evaluation of the expression of RON and SLe X . Of these 15 cases, 8 that showed expression of both antigens were further analyzed by PLA (Supplementary table 2 ). All evaluated cases showed PLA positivity signal with 2 cases displaying a high number of signal corresponding to co-expression in proximity of RON and SLe X . The tumor adjacent mucosa did not show any PLA signal and represents an internal control (Fig. 8) .
Discussion
The altered glycosylation observed in gastric cancer with overexpression of α2-3 sialylated glycans, including the SLe X epitope, has long been associated with aggressive features of the disease and poor prognosis for the patients [5, 7, [41] [42] [43] . However, the biological role of these sialylated glycans remains to be fully understood. In this study, the detailed molecular characterization of gastric cancer cells displaying altered sialylated terminal glycan structures revealed how these glycosylation modifications can lead to functional changes that confer advantage to cancer cells.
Glycosylation alterations induced by ST3GAL4 overexpression
The sialyltransferase ST3GAL4, encoded by the ST3GAL4 gene, catalyzes the addition of α2-3-sialic acid to type 2 extension chains (Galβ1,4GlcNAcβ1-R) generating the precursor of SLe X [13, 21] . In our study we demonstrated that the overexpression of ST3GAL4, in accordance to its substrate specificity, leads to a broad range of glycomic alterations on both N-and O-glycans. Importantly, ST3GAL4 overexpression induces the expression of SLe X which has been described to be commonly upregulated in gastric cancer [41, 44, 45] . Further, we demonstrated for the first time in a gastric cancer context that the upregulation of ST3GAL4, an α2-3 sialyltransferase, not only increases the amount of α2-3 linked sialic acid, but as a consequence, reduces the amount of α2-6-linked sialic acid expressed by the cancer cell, as it has been previously reported in a pancreatic cancer cell line model [46] . The expression levels of other sialyltransferases remained unaltered (Supplementary table 1 ) supporting the assumption that this linkage-shift is rooted in competition for the same asialylated substrate.
Although the general amount of sialylated glycans is described to increase in the context of transformation and malignancy [47, 48] , it is known that the linkage type is of particular importance. Interestingly, the upregulation of α2-6 sialylation has been shown to increase the adhesion of colon and breast cancer cells to extra cellular matrix components and to reduce the invasive capacity of colon and glioma cancer cell lines [49] [50] [51] . Similarly, the increased invasive capacity of ST3GAL4 overexpressing cells previously described [24] could also result from the reduction of α2-6 linked sialic acid modified structures. Our results also showed an almost complete loss of all bisected Nglycan structures in cancer cells overexpressing ST3GAL4. A correlation between sialylation and the activity of GnT-III, the GlcNAc-transferase that leads to the synthesis of bisected N-glycans, has to our knowledge never been reported. Sialyltransferases are normally located in the trans-Golgi and the sialylation resembles a capping event for mature complex and hybrid N-glycans [52] , on the other hand the GnT-III is localized in the medial-Golgi and acts early on the biosynthesis of complex N-glycans [53] . It is important to consider that the subcellular localization of glycosyltransferases and the organization of the secretory compartments are often altered in the context of cancer [54] and this may lead to deviations of the conventional sequential biosynthesis pathway. Moreover, it is known that bisected structures are often reduced in malignancy and this reduction is correlated with tumor progression and poorer prognosis [27, 55, 56] . Our results showed that N-glycans from ST3GAL4 transfected cells display a higher degree of branching resulting in enlargement and increased complexity of structures. In addition, no differences were observed on GnT-V, which is the GlcNAc-transferase that catalyzes the formation of β1-6 branched N-glycans, and GnT-III expression levels (Supplementary table 1) . These enzymes are known to act mutually exclusive on their common glycan acceptor substrate [28, 53, 56] , and therefore the increased branched N-glycans could stem from the reduced amount of bisected structures.
Regarding O-glycosylation, we demonstrated that ST3GAL4 upregulation can also lead to the increased truncation of otherwise elongated O-glycans. The accumulation of short truncated O-glycans like simple carbohydrate antigens are a common feature of gastrointestinal cancer [57] . Our results show that the biosynthesis of early sialylated core-2 structures preclude further elongation of the O-glycan chain.
Our data indicates, for the first time, that several cancer relevant glycomic alterations, such as truncation of O-glycans, reduction of bisected N-glycans, increase of α2-3 sialylation and branching, might not be independent events but may arise coordinated in gastric cancer. The observed changes were further confirmed in an additional glycomic analysis performed in parallel (Tables 2 and 4 in [25] ) [58, 59] . These glycophenotypic alterations may result from genetic and epigenetic alterations, as well as from tumor microenvironment modifications, occurring in the cancer context [60] [61] [62] [63] .
Target proteins displaying aberrant sialylation and its biological implications
In addition, our results revealed that even though the total amount of sialylated N-glycans is not significantly increased, 47 glycoproteins showed significantly increased sialylation in a site specific manner in ST3GAL4 overexpressing cancer cells. Considering that only proteins that are translated into the ER are N-glycosylated and that only those proteins that are conveyed through the Golgi-network undergo addition of sialic acids [64] , it is not surprising that especially transmembrane proteins were found to be affected by the increased sialylation. Furthermore, an interesting observation is that mainly proteins involved in cellular adherence and signaling were affected by this altered glycosylation. Important targets included key players in malignancy, such as integrins, which are known to mediate the interaction of cancer cells to the extracellular matrix [33] . Integrin glycosylation has been shown to modulate the cell adhesion to fibronectin and to affect cancer cell invasion and metastasis [65] . In this study we only considered for validation unique peptide sequences that contained N-glycosylation sites. The majority of enriched peptides, due to increased sialylation on O-glycans or due to common amino acid sequences, were excluded from the analysis. With our approach we could not distinguish between sialic acid linkage and therefore the generation of information of glycopeptides with specific increases of α2-3 sialic acids was precluded. Nonetheless, our approach allowed to identify numerous targets showing altered glycosylation that can be used for follow-up studies. Further, it illustrates that alterations of a single glycosyltransferase can affect a multitude of cancer relevant targets.
Receptor glycosylation as a modulator of activity in cancer
Receptor tyrosine kinases are glycoproteins and key players of transformation and malignant growth [66] . Glycosylation alterations have been demonstrated to modulate receptor activity [24, 67, 68] . In the present study we have focused on the alterations leading to the receptor RON activation. In the last years several efforts have been made to target RON in cancer patients. Currently several tyrosine kinase inhibitors and monoclonal antibodies against RON are applied in clinical or pre-clinical trials for therapeutic efficacy [69] [70] [71] [72] [73] [74] [75] [76] . Our screening revealed that this receptor, which has been described to be an oncogene in gastric cancer [12] , showed an altered glycosylation and concomitant increased activation. RON presents 3 immunoglobulin-like plexin and transcription (IPT) domains that have been described as a cause for constitutive activation in cancer when altered [39, 77] . We demonstrated that Asn841 shows increased sialylation in cells overexpressing ST3GAL4 (Table 5 in [25] ). The Asn841 is located in one of the IPT domains and therefore may underlie the increased activation of this cellular RTK. Further analysis by proximity ligation assay confirmed the glycosylation of RON with SLe X in human gastric carcinoma tissues. These observations support that the altered glycosylation observed in this receptor in gastric cancer may lead to its dysfunctional oncogenic activation and therefore modulating the more aggressive cancer phenotype associated with SLe X expressing tumors. Further studies are warranted to evaluate the biomarker potential of RON glycosylation profile for gastric cancer staging, prognosis and therapeutic response.
Potential application in cancer therapy and future outlook
Hyper-activation of RTKs due to their upregulation or mutations are common oncogenic events that modern medicine tries to evaluate in the process of tumor screening to design a personalized treatment via inhibitors [9] . However, the present screening methods mostly rely on identifying mutations or gene amplifications [78, 79] , and therefore, are not considering post-translational modifications, such as glycosylation, as potential activators in a cancer context. We demonstrated in this work that aberrant glycosylation is an alternative route of RTK activation in cancer, emphasizing the necessity for its evaluation in tumor characterization and patient profiling.
A common drawback of whole glycome analysis is its intrinsic complexity, delaying its application in the clinical routine. Much has to be done to simplify and standardize such glycome analysis and to improve our understanding of glycosylation alterations on specific targets. However, the present work demonstrates the importance of such approaches in addressing complex diseases in combination with large scale genomics, transcriptomics and proteomics. We are convinced that the screening of specific target proteins for glycan alterations can be a future corner stone of clinical tumor characterization complementing the conventional methods and therefore leading to improved molecular characterization of cancers for a better diagnosis, prognosis and therapeutics.
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